Clinical Trial Update: Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

View source ↗

Summary

A retrospective study evaluating Palivizumab use in children with hemodynamically significant congenital heart disease has been completed. Results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: Abbott | Conditions: Severe Respiratory Syncytial Virus Infection | Status: COMPLETED | Results posted: 2011-02-24